Analysts’ Recent Ratings Updates for Corbus Pharmaceuticals (CRBP)

A number of firms have modified their ratings and price targets on shares of Corbus Pharmaceuticals (NASDAQ: CRBP) recently:

• 5/27/2026 – Corbus Pharmaceuticals had its price target lowered by Wedbush from $38.00 to $30.00. They now have an “outperform” rating on the stock.
• 5/26/2026 – Corbus Pharmaceuticals had its “buy” rating reaffirmed by Guggenheim.
• 5/26/2026 – Corbus Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $40.00 price target on the stock.
• 5/22/2026 – Corbus Pharmaceuticals had its price target raised by Mizuho from $40.00 to $44.00. They now have an “outperform” rating on the stock.
• 5/13/2026 – Corbus Pharmaceuticals had its price target lowered by Oppenheimer Holdings, Inc. from $57.00 to $54.00. They now have an “outperform” rating on the stock.
• 5/13/2026 – Corbus Pharmaceuticals had its “buy” rating reaffirmed by Guggenheim. They now have a $45.00 price target on the stock.
• 5/12/2026 – Corbus Pharmaceuticals had its price target lowered by Jefferies Financial Group Inc. from $36.00 to $33.00. They now have a “buy” rating on the stock.
• 4/29/2026 – Corbus Pharmaceuticals is now covered by Guggenheim. They set a “buy” rating and a $45.00 price target on the stock.
• 4/29/2026 – Corbus Pharmaceuticals is now covered by Guggenheim. They set a “buy” rating and a $45.00 price target on the stock.
• 4/25/2026 – Corbus Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 4/20/2026 – Corbus Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Corbus Pharmaceuticals

In other news, insider Nishant C. Saxena bought 9,000 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $7.58 per share, with a total value of $68,220.00. Following the completion of the acquisition, the insider owned 75,300 shares of the company’s stock, valued at $570,774. This represents a 13.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 3.50% of the company’s stock.

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.